Protocol 16-310

Absorb GT1 Bioresorbable Vascular Scaffold System Post-marketing Surveillance Protocol

Statistical Analysis Plan
(Part I: Methodology)

Version 1.0
17FEB2017

Celes Ying

Confidential and Proprietary
Nothing herein is to be disclosed without the expressed written consent of
Abbott Vascular
TABLE OF CONTENTS

1. SYNOPSIS OF STUDY DESIGN AND PROCEDURES .......................................................... 3
   1.1 Purpose of the Statistical Analysis Plan................................................................. 3
   1.2 Study Objectives .................................................................................................. 3
   1.3 Study Design ......................................................................................................... 3
      1.3.1 Primary Endpoints .......................................................................................... 3
      1.3.2 Other Endpoints ............................................................................................ 4
         1.3.2.1 Clinical Endpoints ..................................................................................... 4
         1.3.2.2 Angiographic Endpoints (core lab analysis) .............................................. 5
         1.3.2.3 IVUS/OCT Endpoints (core lab analysis) .................................................. 5
   1.4 Analysis Populations ............................................................................................. 6
   1.5 Sample Size Calculations .................................................................................... 6

2. ANALYSIS CONSIDERATIONS ............................................................................... 7
   2.1 Statistical Methods .............................................................................................. 7
      2.1.1 Descriptive Statistics for Continuous Variables .............................................. 7
      2.1.2 Descriptive Statistics for Categorical Variables ............................................. 9
      2.1.3 Survival Analyses .......................................................................................... 11
   2.2 Subgroups for Analysis ...................................................................................... 11
   2.3 Analysis Window ................................................................................................. 11
   2.4 Handling of Missing Data ................................................................................... 12
   2.5 Adjustments for Covariates ................................................................................. 12
   2.6 Multiplicity Issues .............................................................................................. 12
   2.7 Documentation and Other Considerations ......................................................... 12

3. ACRONYMS AND ABBREVIATIONS ....................................................................... 13

4. REFERENCES ......................................................................................................... 14
1. SYNOPSIS OF STUDY DESIGN AND PROCEDURES

1.1 Purpose of the Statistical Analysis Plan

This statistical analysis plan (SAP) is intended to provide a detailed and comprehensive description of the planned methodology and analysis to be used for Protocol 16-310, the Absorb GT1 Post-marketing surveillance study (hereinafter referred to as “Surveillance”). This plan is based on the Version 1.0, November 8th, 2016 study protocol.

1.2 Study Objectives

The purpose of the Surveillance is to know the frequency and status of adverse device effects and adverse events in order to assure the safety of the new medical device, Absorb GT1 Bioresorbable Vascular Scaffold System (Marketing Approval No. 2800BZX00406000, Nov 2, 2016, hereinafter referred to as “Absorb GT1”), and to collect efficacy and safety information for evaluating clinical use results.

1.3 Study Design

Based on the Ministerial Ordinance on Good Post-marketing Study Practice (GPSP) for Medical Device, the Surveillance will continuously register approximately 2000 subjects with ischemic heart disease potentially indicated for treatment with the Absorb GT1 in two phases. Only on-label use of the Absorb GT1 will occur in this Surveillance until otherwise allowed by the Sponsor although this is a post-marketing surveillance.

Phase 1 will contain the first 250 registered subjects at approximately 45 sites to confirm the efficacy of physician training and to establish optimal training for increasing medical institutions participation in post-marketing evaluation. Subject will continue to register in Phase 2 at up to 200 sites until all 2000 subjects are registered in the Surveillance. The main purpose of Phase 2 is to confirm safety. Data will be collected until all subjects complete 5-year follow-up. All subjects will have a follow-up telephone contact or office visit at 3 months and 1, 2, 3, 4 and 5 years.

1.3.1 Primary Endpoints

Phase 1 (250 subjects)

All subjects will be treated by imaging-guided implantation technique using IVUS/OCT. At least first 150 subjects will be analyzed by the core lab.

- Exclusion of very small vessels (Evaluation of RVD to exclude small vessels)
- Scaffold apposition assessed by intravascular imaging (analyzed by the IVUS/OCT core lab)
Phase 1 + Phase 2 (2000 subjects)

- Device deficiency at procedure of implantation
- Scaffold thrombosis (ST)
  - If ST rate at 3 months is \( \leq 0.9\% \), then commercial sale will be started
  - If ST rate at 2 years is \( \geq 1.5\% \), then investigation will be implemented to identify the cause

Scaffold thrombosis events occurred during the Surveillance will be adjudicated by a scaffold thrombosis image-review committee.

1.3.2 Other Endpoints

To be evaluated per typical DES clinical studies.

1.3.2.1 Clinical Endpoints

Clinical endpoints will be evaluated in hospital and at each follow-up time point (3 months, and 1, 2, 3, 4, and 5 years).

- Component endpoints
  - Death (Cardiac/Vascular/Non-Cardiovascular)
  - Myocardial Infarction (TV-MI/NTV-MI)
  - Target Lesion Revascularization (ID-TLR/NID-TLR)
  - Target Vessel Revascularization (ID-TVR/NID-TVR)
  - All coronary revascularization

- Composite endpoints
  - DMR (All death/All MI/All revascularization)
  - TVF (Cardiac death/All MI/ID-TVR)
  - MACE (Cardiac death/All MI/ID-TLR)
  - TLF (Cardiac death/TV-MI/ID-TLR)
  - Cardiac death/All MI

Clinical events committee (CEC) will evaluate all deaths and suspected of MIs for 3 years maximally. Surveillance sites will cooperate in providing materials needed to adjudication (e.g., death report, discharged summary) to the Sponsor, if a patient is dead or is suspected to have MI.
1.3.2.2 Angiographic Endpoints (core lab analysis)

Pre-procedure
- Morphology
- TIMI blood flow
- Lesion length
- RVD
- MLD
- %DS

Post-procedure
- TIMI blood flow
- RVD (Proximal, Distal, Segment)
- MLD (Proximal, Distal, In-stent, In-segment)
- %DS (Proximal, Distal, In-stent, In-segment)
- Acute gain (In-stent, In-segment)

1.3.2.3 IVUS/OCT Endpoints (core lab analysis)

The IVUS/OCT endpoints will be updated according to the finalized definitions from the core labs.

Pre-procedure (or after pre-dilatation)
- Lumen diameter
- Lumen area

Post-procedure
- Lumen diameter
- Lumen area
- MLA
- Incomplete apposition of the Absorb GT1 strut (per lesion, per strut)
- Fracture of the Absorb GT1 strut
1.4 Analysis Populations

The following populations will be used for clinical evaluation:

- **Intent-to-Treat (ITT)**
  The intent-to-treat population is defined as all subjects registered in the study, including subjects who had failed Absorb GT1 procedure. This population will only be applied to the evaluation of acute success.

- **Full Analysis Set (FAS)**
  The full analysis set population is defined as all subjects registered in the study who have had at least one Absorb GT1 implanted.

- **Absorb Only Population (AOP)**
  The Absorb only population is defined as all subjects registered in the study who have had only Absorb GT1 implanted.

1.5 Sample Size Calculations

The ST rate through 1 year was 1.5% in both the AVJ-301 and the ABSORB III clinical trials. In the ABSORB III clinical trial, a total of 19 events of definite/probable ST were reported through 1 year. Of those, 18 events occurred within 3 months post-procedure. Hence, it is reasonable to assume that the ST rates at 3 months and 1 year are similar.

The ST rate in target lesion with RVD ≥ 2.25 mm was 0.9% in the ABSORB III clinical trial and was used as an assumption for the sample size calculation. The half widths of the 95% confidence intervals (CI) for different sample sizes are presented in the table below. The half width of 95% CI decreases from 0.6% to 0.4% when a sample size is increased from 1000 to 2000. However, further increase in the sample size does not result in a decrease in the half width of 95% CI. Therefore, the sample size of the Surveillance was established as 2000 patients.

<table>
<thead>
<tr>
<th>N=1000</th>
<th>N=1500</th>
<th>N=2000</th>
<th>N=2500</th>
<th>N=3000</th>
</tr>
</thead>
<tbody>
<tr>
<td>ST Rate</td>
<td>0.9%</td>
<td>0.9%</td>
<td>0.9%</td>
<td>0.9%</td>
</tr>
<tr>
<td>½ of 95% CI</td>
<td>0.6%</td>
<td>0.5%</td>
<td>0.4%</td>
<td>0.4%</td>
</tr>
</tbody>
</table>
2. ANALYSIS CONSIDERATIONS

2.1 Statistical Methods

Baseline demographic, clinical, angiographic, IVUS/OCT, procedural, and device data, and treatment results will be summarized using descriptive summary statistics.

2.1.1 Descriptive Statistics for Continuous Variables

For continuous variables (e.g., age, percent diameter stenosis and lesion length), results will be summarized with the numbers of observations, means, and standard deviations and where specified in the table mockups, with quartiles, minimums, maximums, and 95% confidence intervals for the means as per the table mockups. Differences between two comparison groups of interest, where specified, will be summarized with relative risks, the differences of the two means, and 95% confidence intervals for the difference between the means. These calculations will be done under the assumption that the data for the two groups of interest are independent and approximately normal in distribution. The confidence interval for the difference of two means will be calculated under the assumption of unequal variances. If the asymptotic assumptions fail, then nonparametric summary statistics (medians, 25th and 75th percentiles) may be displayed as an alternative.

Formulas for calculation of the confidence intervals for the continuous variables are given below:

1. 100(1 - α)% Confidence Interval For A Single Mean

\[
\bar{x} \pm t_{\alpha/2} \frac{s}{\sqrt{n}}
\]

where:
- \(\bar{x}\) = sample mean
- s = sample standard deviation
- n = sample size
- \(t_{\alpha/2}\) = the alpha/2 t - statistic for \(n - 1\) degrees of freedom

2. 100(1-α)% Confidence Interval For The Difference of Two Means Under The Assumption Of Equal Variances Between The Two Groups

\[
\left(\bar{x}_1 - \bar{x}_2\right) \pm t_{\alpha/2} \sqrt{s_p^2 \left(\frac{1}{n_1} + \frac{1}{n_2}\right)}
\]
where:

\[ \bar{x}_1 = \text{sample mean for group 1} \quad \bar{x}_2 = \text{sample mean for group 2} \]

\[ s_p^2 = \frac{(n_1 - 1)s_1^2 + (n_2 - 1)s_2^2}{n_1 + n_2 - 2} \]

\[ s_1 = \text{sample standard deviation for group 1} \quad s_2 = \text{sample standard deviation for group 2} \]

\[ n_1 = \text{sample size for group 1} \quad n_2 = \text{sample size for group 2} \]

\[ t_{\alpha/2} = \text{the alpha/2 t - statistic for } n_1 + n_2 - 2 \text{ degrees of freedom} \]

3. 100(1-\(\alpha\)) % Confidence Interval for the Difference of Two Means under the Assumption of Unequal Variances between the Two Groups\(^2\)

\[ (\bar{x}_1 - \bar{x}_2) \pm t_{\alpha/2} SED \]

With the degrees of freedom for the approximate t statistic is determined by Satterthwaite’s formula\(^3\) as follows:

\[ df = \frac{(w_1 + w_2)^2}{\frac{w_1^2}{n_1 - 1} + \frac{w_2^2}{n_2 - 1}} \]

where:

\[ \bar{x}_1 = \text{sample mean for group 1} \]

\[ \bar{x}_2 = \text{sample mean for group 2} \]

\[ s_1 = \text{sample standard deviation for group 1} \]

\[ s_2 = \text{sample standard deviation for group 2} \]

\[ n_1 = \text{sample size for group 1} \]

\[ n_2 = \text{sample size for group 2} \]

\[ SED = \sqrt{\frac{s_1^2}{n_1} + \frac{s_2^2}{n_2}} \]

\[ w_1 = \frac{s_1^2}{n_1} \]

\[ w_2 = \frac{s_2^2}{n_2} \]
2.1.2 Descriptive Statistics for Categorical Variables

For categorical variables such as gender, MACE and TVF, results will be summarized with subject counts and percentages/rates, and where specified in the table mockups, with exact 95% Clopper-Pearson confidence intervals. Differences between the two comparison groups of interest, when specified, will be summarized with the difference in percentages and the Newcombe score 95% confidence interval for the difference of two percentages.

For efficacy and safety endpoint(s), relative risks (i.e., the ratio of rates), confidence interval for the relative risks, the difference in rates and the confidence interval for difference in rates (using previously-described formulas), and p-values may also be presented for hypothesis generating purposes. The p-values will be based on either Pearson’s Chi-square test or Fisher’s exact test by checking the expected frequency for each cell in the 2x2 contingency table against Cochran’s rule, i.e., if the expected frequencies for all cells are ≥ 5, then Pearson’s Chi-square test will be used, otherwise Fisher’s exact test will be used.

For the determination of event rates at all time points (in-hospital, 3 months and 1, 2, 3, 4 and 5 years), the denominators are defined as below based on the type of events.

- **Death/MI/Revascularization (DMR) event**
  Subjects will be included in the analysis if they either had the DMR event by that time or they did not have the DMR event but had follow-up through that time point. In other words, subjects will be included in a given analysis if it can be determined whether or not the subject would have had the DMR event by the time point.

- **Stent/Scaffold Thrombosis (ST)**
  Subjects will be included in the analysis if they either had the ST by that time or they did not have ST but had follow-up through that time point. In other words, subjects will be included in a given analysis if it can be determined whether or not the subject would have had ST by the time point.

Formulas for calculating confidence intervals for the categorical variables are given below.

1. 100(1-α) % Exact Clopper-Pearson Confidence Interval for A Single Proportion

\[
\text{Lower Confidence Limit} = \frac{x}{x + (n - x + 1)} - \left(\frac{2(n - x + 1)x}{1 - \frac{1}{2} (2(n - x + 1)x)}\right)
\]
Upper Confidence Limit = \[ \frac{(x + 1)F_{\frac{\alpha}{2}}(2(x + 1), 2(n - x))}{n - x + (x + 1)F_{\frac{\alpha}{2}}(2(x + 1), 2(n - x))} \]

where:

- \( n \) = sample size
- \( x \) = number of "events"
- \( F_{\frac{\alpha}{2}}(df_1, df_2) \) = the (1 - \( \alpha \)/2) F-statistic for degrees of freedom \( df_1 \) and \( df_2 \)

2. 100(1-\( \alpha \))% Newcombe Score Confidence Interval for the Difference of Two Proportions\(^4\)

a. 100(1-\( \alpha \))% Wilson Score Confidence Interval for A Single Proportion\(^6\)

Lower Confidence Limit = \[ \hat{p} - \frac{Z_{\alpha/2}^2}{n} - \frac{Z_{\alpha/2}^2}{n}(\hat{p}(1 - \hat{p}) + \frac{Z_{\alpha/2}^2}{4n})/n \]

Upper Confidence Limit = \[ \hat{p} + \frac{Z_{\alpha/2}^2}{n} + \frac{Z_{\alpha/2}^2}{n}(\hat{p}(1 - \hat{p}) + \frac{Z_{\alpha/2}^2}{4n})/n \]

where:

- \( \hat{p} = x/n \)
- \( n \) = sample size
- \( x \) = number of "events"
- \( Z_{\alpha/2} = 100(1 - \alpha/2) \)th percentile of the standard normal distribution

b. 100(1-\( \alpha \))% Newcombe Score Confidence Interval for the Difference of Two Proportions\(^4\)

Lower Confidence Limit = \( \hat{p}_1 - \hat{p}_2 - Z_{\alpha/2} \sqrt{U_1(1 - L_1)/n_1 + U_2(1 - L_2)/n_2} \)

Upper Confidence Limit = \( \hat{p}_1 - \hat{p}_2 + Z_{\alpha/2} \sqrt{U_1(1 - L_1)/n_1 + U_2(1 - L_2)/n_2} \)

where:

- \( \hat{p}_1 = \) sample proportion for group 1
- \( \hat{p}_2 = \) sample proportion for group 2
- \( L_1 \) and \( U_1 \) are the lower and upper Wilson Score confidence limits for \( p_1 \)
- \( L_2 \) and \( U_2 \) are the lower and upper Wilson Score confidence limits for \( p_2 \)
- \( Z_{\alpha/2} = 100(1 - \alpha/2) \)th percentile of the standard normal distribution
2.1.3 Survival Analyses

Survival analysis will be conducted to analyze time-to-event variables. Subjects without events will be censored at their last known event-free time point. Survival curves will be constructed using Kaplan-Meier estimates.

Summary tables for safety and efficacy endpoints will include number of subjects at risk, number of censored subjects, number of events, failure rates (Kaplan-Meier estimates) and standard error of the survival rate for each time interval. For the primary analysis report, all available data will be used.

2.2 Subgroups for Analysis

Subgroups, including but not limited to the following, will be evaluated for the FAS and AOP. Baseline demographics, baseline subject characteristics, procedure information, morphology, quantitative coronary angiography, IVUS/OCT, and hierarchical/non-hierarchical adverse event data will be summarized with descriptive statistics. Comparisons will be made within the subgroup when appropriate.

Sex:
- Male
- Female

Diabetes:
- All Diabetes Mellitus
- Non-Diabetes Mellitus

Stent diameter:
- 2.5 mm
- 3.0 mm
- 3.5 mm

2.3 Analysis Window

- Baseline (pre-procedure)
- Procedure
- Post-procedure to discharge
- 3 months (by visit preferred; by telephone is allowed) (Day 90 ± 14 days)
- 1 year (by visit preferred; by telephone is allowed) (Day 365 ± 28 days)
• 2 years (by visit or telephone) (Day 730 ± 28 days)
• 3 years (by visit or telephone) (Day 1095 ± 28 days)
• 4 years (by visit or telephone) (Day 1460 ± 28 days)
• 5 years (by visit or telephone) (Day 1825 ± 28 days)

Scheduled imaging follow-up is not required for this surveillance. If any imaging is performed as site standard practice or is performed for diagnosis, the imaging modality and results should be recorded in case report forms.

2.4 Handling of Missing Data

All analyses will be based on available data with missing data excluded. Any unused or spurious data will be noted as appropriate in the final report.

2.5 Adjustments for Covariates

Unless otherwise specified, no adjustments for covariates will be made for any of the variables in the analyses.

2.6 Multiplicity Issues

There are no hypothesis testing for the clinical endpoints planned for this study, therefore no multiplicity issues need to be addressed in this study plan.

2.7 Documentation and Other Considerations

All analyses will be performed using SAS® for Windows, version 9.3 or higher.
3. ACRONYMS AND ABBREVIATIONS

<table>
<thead>
<tr>
<th>Acronym/Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>%DS</td>
<td>Percent Diameter Stenosis</td>
</tr>
<tr>
<td>AOP</td>
<td>Absorb Only Population</td>
</tr>
<tr>
<td>BVS</td>
<td>Bioresorbable Vascular Scaffold</td>
</tr>
<tr>
<td>CEC</td>
<td>Clinical Event Committee</td>
</tr>
<tr>
<td>DMR</td>
<td>All Death/All MI/All Revascularization</td>
</tr>
<tr>
<td>FAS</td>
<td>Full Analysis Set</td>
</tr>
<tr>
<td>ITT</td>
<td>Intent-To-Treat</td>
</tr>
<tr>
<td>IVUS</td>
<td>Intravascular Ultrasound</td>
</tr>
<tr>
<td>MACE</td>
<td>Major Adverse Cardiac Event</td>
</tr>
<tr>
<td>MI</td>
<td>Myocardial Infarction</td>
</tr>
<tr>
<td>MLA</td>
<td>Minimal Lumen Area</td>
</tr>
<tr>
<td>MLD</td>
<td>Minimum Luminal Diameter</td>
</tr>
<tr>
<td>OCT</td>
<td>Optical Coherence Tomography</td>
</tr>
<tr>
<td>PMS</td>
<td>Post-marketing surveillance</td>
</tr>
<tr>
<td>QCA</td>
<td>Quantitative Coronary Angiography</td>
</tr>
<tr>
<td>RVD</td>
<td>Reference Vessel Diameter</td>
</tr>
<tr>
<td>SAP</td>
<td>Statistical Analysis Plan</td>
</tr>
<tr>
<td>ST</td>
<td>Scaffold/Stent Thrombosis</td>
</tr>
<tr>
<td>TIMI</td>
<td>Thrombolysis in Myocardial Infarction</td>
</tr>
<tr>
<td>TLR</td>
<td>Target Lesion Revascularization</td>
</tr>
<tr>
<td>TVF</td>
<td>Target Vessel Failure</td>
</tr>
<tr>
<td>TVR</td>
<td>Target Vessel Revascularization</td>
</tr>
</tbody>
</table>
4. REFERENCES